AU2002347910A1 - Methods and compositions for targeting proteins across the blood brain barrier - Google Patents
Methods and compositions for targeting proteins across the blood brain barrierInfo
- Publication number
- AU2002347910A1 AU2002347910A1 AU2002347910A AU2002347910A AU2002347910A1 AU 2002347910 A1 AU2002347910 A1 AU 2002347910A1 AU 2002347910 A AU2002347910 A AU 2002347910A AU 2002347910 A AU2002347910 A AU 2002347910A AU 2002347910 A1 AU2002347910 A1 AU 2002347910A1
- Authority
- AU
- Australia
- Prior art keywords
- compositions
- methods
- brain barrier
- blood brain
- targeting proteins
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/65—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/06—Fusion polypeptide containing a localisation/targetting motif containing a lysosomal/endosomal localisation signal
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
Applications Claiming Priority (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US32965001P | 2001-10-16 | 2001-10-16 | |
US60/329,650 | 2001-10-16 | ||
US10/136,639 US20030072761A1 (en) | 2001-10-16 | 2002-04-30 | Methods and compositions for targeting proteins across the blood brain barrier |
US10/136,639 | 2002-04-30 | ||
US10/136,841 US7396811B2 (en) | 2001-04-30 | 2002-04-30 | Subcellular targeting of therapeutic proteins |
US10/136,841 | 2002-04-30 | ||
US38445202P | 2002-05-29 | 2002-05-29 | |
US60/384,452 | 2002-05-29 | ||
US38601902P | 2002-06-05 | 2002-06-05 | |
US60/386,019 | 2002-06-05 | ||
US40881602P | 2002-09-06 | 2002-09-06 | |
US60/408,816 | 2002-09-06 | ||
PCT/US2002/032996 WO2003032913A2 (en) | 2001-10-16 | 2002-10-16 | Methods and compositions for targeting proteins across the blood brain barrier |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2002347910A1 true AU2002347910A1 (en) | 2003-04-28 |
Family
ID=27558195
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2002347910A Abandoned AU2002347910A1 (en) | 2001-10-16 | 2002-10-16 | Methods and compositions for targeting proteins across the blood brain barrier |
AU2002362930A Abandoned AU2002362930A2 (en) | 2001-10-16 | 2002-10-16 | Methods and compositions for targeting underglycosylated proteins across the blood brain barrier |
AU2010214643A Abandoned AU2010214643A1 (en) | 2001-10-16 | 2010-08-25 | Methods and compositions for targeting underglycosylated proteins across the blood brain barrier |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2002362930A Abandoned AU2002362930A2 (en) | 2001-10-16 | 2002-10-16 | Methods and compositions for targeting underglycosylated proteins across the blood brain barrier |
AU2010214643A Abandoned AU2010214643A1 (en) | 2001-10-16 | 2010-08-25 | Methods and compositions for targeting underglycosylated proteins across the blood brain barrier |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1446007A4 (en) |
JP (2) | JP2005506340A (en) |
AU (3) | AU2002347910A1 (en) |
CA (1) | CA2463473A1 (en) |
IL (1) | IL161352A0 (en) |
WO (2) | WO2003032913A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003237314B2 (en) * | 2002-05-29 | 2010-03-04 | Biomarin Pharmaceutical Inc. | Targeted therapeutic proteins |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7629309B2 (en) | 2002-05-29 | 2009-12-08 | Zystor Therapeutics, Inc. | Targeted therapeutic proteins |
EP1436316B1 (en) | 2001-04-30 | 2008-01-23 | ZyStor Therapeutics , Inc. | Subcellular targeting of therapeutic proteins |
US7560424B2 (en) | 2001-04-30 | 2009-07-14 | Zystor Therapeutics, Inc. | Targeted therapeutic proteins |
JP2005506340A (en) * | 2001-10-16 | 2005-03-03 | シムバイオンティクス インコーポレイテッド | Methods and compositions for targeting underglycosylated proteins across the blood brain barrier |
US20030072761A1 (en) | 2001-10-16 | 2003-04-17 | Lebowitz Jonathan | Methods and compositions for targeting proteins across the blood brain barrier |
ATE465250T1 (en) * | 2004-02-10 | 2010-05-15 | Zystor Therapeutics Inc | ACID ALPHA-GLUCOSIDASE AND FRAGMENTS THEREOF |
CA3184105A1 (en) | 2007-07-27 | 2009-02-05 | Armagen Inc. | Methods and compositions for increasing alpha-l-iduronidase activity in the cns |
ES2511844T3 (en) * | 2007-12-21 | 2014-10-23 | F. Hoffmann-La Roche Ag | Antibody formulation |
US20110223147A1 (en) | 2008-05-07 | 2011-09-15 | Zystor Therapeutics, Inc. | Lysosomal targeting peptides and uses thereof |
WO2010148253A2 (en) | 2009-06-17 | 2010-12-23 | Zystor Therapeutics, Inc. | Formulations for lysosomal enzymes |
CA2803003C (en) | 2010-06-25 | 2022-11-22 | Shire Human Genetic Therapies, Inc. | Methods and compositions for cns delivery of arylsulfatase a |
NZ605865A (en) | 2010-06-25 | 2015-07-31 | Shire Human Genetic Therapies | Cns delivery of therapeutic agents |
KR20140005842A (en) | 2010-06-25 | 2014-01-15 | 샤이어 휴먼 지네틱 테라피즈 인크. | Methods and compositions for cns delivery of heparan n-sulfatase |
UA115649C2 (en) | 2010-06-25 | 2017-12-11 | Шае Хюмен Дженетік Терапіс, Інк. | Methods and compositions for cns delivery of iduronate-2-sulfatase |
ES2895655T3 (en) | 2010-06-25 | 2022-02-22 | Shire Human Genetic Therapies | Methods and compositions for CNS administration of iduronate-2-sulfatase |
NZ605871A (en) | 2010-06-25 | 2015-02-27 | Shire Human Genetic Therapies | Treatment of sanfilippo syndrome type b |
MX2014006594A (en) * | 2011-12-01 | 2015-09-16 | Angiochem Inc | Targeted lysosomal enzyme compounds. |
EP2793922B1 (en) | 2011-12-23 | 2019-10-30 | Shire Human Genetic Therapies, Inc. | Stable formulations for cns delivery of arylsulfatase a |
EP2885318A4 (en) | 2012-08-14 | 2016-03-30 | Angiochem Inc | Peptide-dendrimer conjugates and uses thereof |
DK2925776T3 (en) | 2012-11-27 | 2018-09-03 | Biomarin Pharm Inc | TARGETED THERAPEUTIC LYSOSOMAL ENZYMUS FUSION PROTEINS AND APPLICATIONS THEREOF |
JP6541581B2 (en) | 2013-03-15 | 2019-07-10 | グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー2)、リミテッドGlaxosmithkline Intellectual Property (No.2) Limited | Low concentration antibody preparation |
KR20160138282A (en) | 2014-04-01 | 2016-12-02 | 스위디쉬 오르펀 바이오비트럼 에이비(피유비엘) | Modified sulfamidase and production thereof |
US10980892B2 (en) | 2015-06-15 | 2021-04-20 | Angiochem Inc. | Methods for the treatment of leptomeningeal carcinomatosis |
EP3419651B1 (en) | 2016-02-24 | 2023-10-25 | BioMarin Pharmaceutical Inc. | Improved naglu fusion protein formulation |
CA3098674A1 (en) * | 2018-04-30 | 2019-11-07 | Amicus Therapeutics, Inc. | Gene therapy constructs and methods of use |
BR112021006829A2 (en) | 2018-10-10 | 2021-07-20 | Amicus Therapeutics, Inc. | polypeptide compositions stabilized with disulfide bonds and methods of use |
EP3898689A1 (en) | 2018-12-20 | 2021-10-27 | Armagen, Inc. | Purification of iduronate-2-sulfatase immunoglobulin fusion protein |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4801575A (en) * | 1986-07-30 | 1989-01-31 | The Regents Of The University Of California | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
US5672683A (en) * | 1989-09-07 | 1997-09-30 | Alkermes, Inc. | Transferrin neuropharmaceutical agent fusion protein |
WO1991004014A1 (en) * | 1989-09-21 | 1991-04-04 | Synergen, Inc. | Method for transporting compositions across the blood brain barrier |
US6472140B1 (en) * | 1997-09-05 | 2002-10-29 | The General Hospital Corporation | α-2- macroglobulin therapies and drug screening methods for Alzheimer's disease. |
WO2003102583A1 (en) * | 2002-05-29 | 2003-12-11 | Symbiontics, Inc. | Targeted therapeutic proteins |
EP1436316B1 (en) * | 2001-04-30 | 2008-01-23 | ZyStor Therapeutics , Inc. | Subcellular targeting of therapeutic proteins |
JP2005506340A (en) * | 2001-10-16 | 2005-03-03 | シムバイオンティクス インコーポレイテッド | Methods and compositions for targeting underglycosylated proteins across the blood brain barrier |
-
2002
- 2002-10-16 JP JP2003535542A patent/JP2005506340A/en active Pending
- 2002-10-16 CA CA002463473A patent/CA2463473A1/en not_active Abandoned
- 2002-10-16 AU AU2002347910A patent/AU2002347910A1/en not_active Abandoned
- 2002-10-16 IL IL16135202A patent/IL161352A0/en unknown
- 2002-10-16 AU AU2002362930A patent/AU2002362930A2/en not_active Abandoned
- 2002-10-16 WO PCT/US2002/032996 patent/WO2003032913A2/en not_active Application Discontinuation
- 2002-10-16 WO PCT/US2002/032968 patent/WO2003032727A1/en active Application Filing
- 2002-10-16 EP EP02801739A patent/EP1446007A4/en not_active Withdrawn
-
2009
- 2009-06-16 JP JP2009143436A patent/JP2009203241A/en active Pending
-
2010
- 2010-08-25 AU AU2010214643A patent/AU2010214643A1/en not_active Abandoned
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003237314B2 (en) * | 2002-05-29 | 2010-03-04 | Biomarin Pharmaceutical Inc. | Targeted therapeutic proteins |
Also Published As
Publication number | Publication date |
---|---|
EP1446007A4 (en) | 2005-12-07 |
AU2002362930A2 (en) | 2003-04-28 |
WO2003032727A1 (en) | 2003-04-24 |
EP1446007A1 (en) | 2004-08-18 |
AU2010214643A1 (en) | 2010-09-16 |
WO2003032913A9 (en) | 2004-04-29 |
IL161352A0 (en) | 2004-09-27 |
JP2009203241A (en) | 2009-09-10 |
WO2003032913A3 (en) | 2004-08-12 |
CA2463473A1 (en) | 2003-04-24 |
JP2005506340A (en) | 2005-03-03 |
WO2003032913A2 (en) | 2003-04-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2002347910A1 (en) | Methods and compositions for targeting proteins across the blood brain barrier | |
AU2002321888A1 (en) | Medical needle | |
AU2002238351A1 (en) | Soft cannula | |
AU2002307479A1 (en) | Magnetic field stimulation techniques | |
HK1068812A1 (en) | Drug preparations | |
AU2002253039A1 (en) | Tramadol-based medicament | |
AU2002359919A1 (en) | Syringe | |
AU2002317759A1 (en) | Ophthalmoscope | |
AU2002361092A1 (en) | Syringe | |
AU2002327860A1 (en) | Diagnostic methods | |
AU2002244055A1 (en) | Fra-1 expression in brain cancer | |
AU2002335667A1 (en) | Modified reoviral therapy | |
AU2003217392A1 (en) | Methods for identifying targeting domains and methods and compositions comprising the same | |
AU2002365148A1 (en) | Human ras interacting protein | |
AU2002360333A1 (en) | Human angiomotin-like protein 1 | |
AU2002232563A1 (en) | Compounds for therapy and diagnosis and methods for using same | |
AU2001284748A1 (en) | Reaper protein | |
AU2002257630A1 (en) | Human mrp5-like protein | |
AU2002367463A1 (en) | NOVEL p53BP2 COMPOUNDS FOR THERAPY AND DIAGNOSIS AND METHODS FOR USING SAME | |
AU2002326909A1 (en) | Neurotransmission-associated proteins | |
AU2002308997A1 (en) | Protein preparation | |
AU2002256915A1 (en) | Drug preparations | |
AUPR310501A0 (en) | Medical composition | |
AU2002243916A1 (en) | Timm8b-related protein | |
AU2002248517A1 (en) | Rax-related protein |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |